We evaluated differences in long-term outcomes of invasive lobular carcinoma vs breast cancers of no special type treated with anthracycline-based adjuvant chemotherapy using 4 National Surgical Adjuvant Breast and Bowel Project randomized phase III trials (B-22, B-25, B-28, and B-30). Our cohort included 11 251 patients with no special type and 1231 with invasive lobular carcinoma. Patients with invasive lobular carcinoma were older, had larger and more frequently estrogen receptor-positive tumors, and more positive lymph nodes. During early follow-up (0-5 years), patients with invasive lobular carcinoma had fewer recurrences (hazard ratio [HR] = 0.797, 95% confidence interval [CI] = 0.685 to 0.929) and deaths (HR = 0.756, 95% CI = 0.623 to 0.917). After 5 years, patients with invasive lobular carcinoma had more recurrences (HR = 1.30, 95% CI = 1.085 to 1.558) and deaths (HR = 1.044, 95% CI = 0.898 to 1.214). Conditional probability analysis showed statistically significant interactions between time-period and histologic type for recurrences (P < .001) and deaths (P < .001). Patients with invasive lobular carcinoma have elevated risk of late recurrence and death compared with patients with no special type cancers.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11717417 | PMC |
| http://dx.doi.org/10.1093/jnci/djae188 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) includes simple steatosis and metabolic dysfuncion-associated steatohepatitis (MASH), with fibrosis in MASH serving as a critical prognostic marker. This study investigates the effects of Roux-en-Y gastric bypass (RYGB) on fibrotic MASH, assessed using the fibrotic NASH index (FNI) and the non-invasive NASH detection score (NI-NASH-DS), as well as provides further data on the diagnostic accuracy of both scores.
Methods: A retrospective cohort study was conducted involving 104 individuals (91.
Invasive Lobular Carcinoma (ILC), a distinct subtype of breast cancer is hallmarked by E-Cadherin loss, slow proliferation, and strong hormone receptor positivity. ILC faces significant challenges in clinical management due to advanced stage at diagnosis, late recurrence, and development of resistance to endocrine therapy - a cornerstone of ILC treatment. To elucidate the mechanisms underlying endocrine resistance in ILC, ILC cell lines (MDA-MB-134-VI, SUM44PE) were generated to be resistant to tamoxifen, a selective estrogen receptor modulator.
View Article and Find Full Text PDFRisk Factors for Positive Resection Margins Following Breast-Conserving Surgery.
Cureus
December 2024
Department of Breast, Plastic and Reconstructive Surgery, Royal Hallamshire Hospital, Sheffield, GBR.
Background The incidence of margin re-excision following breast conserving surgery (BCS) is a quality measure in the National Health Service. The threshold is less than 20% of all BCS procedures. Despite three decades of studies and a wealth of literature identifying multiple factors associated with increased risk for margin involvement, an accepted threshold rate affecting one in five procedures remains high.
View Article and Find Full Text PDFBackground: Evaluation of the prognostic performance and clinical utility of the MammaPrint 70-gene signature in early-stage invasive lobular carcinoma (ILC) for whom such analyses in a randomized trial is awaited.
Patients And Methods: Exploratory subgroup analysis of MINDACT trial patients with centrally assessed histology (n = 5929) with invasive breast cancer of no-special-type (NST), or pure ILC. In the trial patients were categorized based on the 70-gene signature for genomic risk and modified Adjuvant!Online for clinical risk.
A Comprehensive Analysis of Neoadjuvant Chemotherapy in Breast Cancer: Adverse Events, Clinical Response Rates, and Surgical and Pathological Outcomes-Bozyaka Experience.
Cancers (Basel)
January 2025
Bozyaka Education and Research Hospital, University of Health Sciences Turkey, 35170 Izmir, Turkey.
To evaluate the neoadjuvant chemotherapy (NACTx) process in breast cancer (BC), its significant treatment-related adverse events (trAEs), tumor clinical response rates, and surgical and pathological outcomes, and to analyze factors influencing cavity shaving and axillary lymph node dissection (ALND) following sentinel lymph node biopsy (SLNB). A comprehensive retrospective study was conducted at a single center on patients who received NACTx for BC between 2015 and 2021. Medical records of 242 patients were reviewed.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!